REGULATORY

FY2024 CEA Reform Outline OK’ed, Price Adjustment Range Up for Continued Debate

December 14, 2023

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

A subcommittee of a Japanese reimbursement policy panel on December 13 approved the FY2024 reform outline for the cost-effectiveness assessment (CEA) system, with no objection raised. The range of price adjustments will be subject to continued discussions. The CEA subcommittee…

To read the full story

Is Case of Leqembi a “Steppingstone” to New CEA Price Adjustment Rule? Pharma Industry on Guard
January 30, 2024
Pharma Fiercely Opposes Proposed CEA Cut into Drug Base Price: Chuikyo Hearing
November 20, 2023

REGULATORY

LDP, Ishin Still at Odds on Social Security Reform; Pharma Role in Chuikyo Gains Traction
June 19, 2026
MHLW Panel OKs Technical Review Group for OTC-Like Drug Charge System
June 19, 2026
MHLW Official Warns of High Risks from GLP-1 Use in Cosmetic Weight Loss
June 19, 2026
LDP to Launch Study Group on Lag and Loss of Pediatric Cancer Drugs
June 19, 2026
LDP Patch League Urges Drug Price Support as Costs Continue to Climb
June 19, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Adaptation, Diversification Key as Drug Wholesalers Face Profit Squeeze

By Tatsuya Otsuka

Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…